Key result
Early evolocumab linked to ~58% lower 3-month MACE vs. statin monotherapy in CHIP-NSTEACS.
Why the study?
Non-revascularized CHIP-NSTEACS patients represent an ultra-high-risk group with limited data on the efficacy of early evolocumab added to statin therapy for lipid lowering, inflammation reduction, and short-term outcomes.
Does early evolocumab added to high-intensity statin therapy reduce 3-month MACE in non-revascularized CHIP-NSTEACS patients?
Cohort (n=186)
No
Does early evolocumab added to high-intensity statin therapy reduce 3-month MACE in non-revascularized CHIP-NSTEACS patients?
Hazard Ratio: 0.42 (95% CI 0.25–0.71)
Absolute Event Rate: 11.96% vs 28.72%
Absolute Risk Reduction: 16.8%
p-value: p=0.001
Early initiation of evolocumab on top of high-intensity statin significantly reduces short-term MACE in ultra-high-risk CHIP-NSTEACS patients ineligible for revascularization, driven by both rapid lipid lowering and profound systemic anti-inflammatory effects.
Objective To evaluate the lipid-lowering efficacy, anti-inflammatory activity, and short-term prognostic benefit of early evolocumab plus statin in complex high-risk indicated non-revascularized non-ST-elevation acute coronary syndrome (CHIP-NSTEACS) patients. Methods This single-center retrospective cohort study consecutively enrolled 186 CHIP-NSTEACS patients hospitalized from January 2022 to December 2024. Patients were divided into an observation group (high-intensity statin + evolocumab initiated within 48 h of admission, n = 92) and a control group (statin monotherapy, n = 94). Inverse probability of treatment weighting (IPTW) was used to balance baseline covariates. Longitudinal changes in lipid profiles and high-sensitivity C-reactive protein (hs-CRP) were analyzed using repeated-measures ANOVA. The primary endpoint was 3-month major adverse cardiovascular events (MACE). Multivariate Cox regression and Fine-Gray competing risk models were used for survival analysis. Results Baseline characteristics were well-balanced after IPTW (all standardized mean differences <0.1). At 3 months, LDL-C reduction was 61.3% in the observation group vs. 32.2% in the control group ( P < 0.001), with target achievement rates (<1.8 mmol/L) of 89.1% vs. 27.7% ( P < 0.001). Evolocumab also significantly reduced lipoprotein(a) and hs-CRP (48.7% vs. 26.1% at 1 month, P < 0.001). The 3-month MACE incidence was lower in the observation group (11.96% vs. 28.72%, P = 0.004), driven by reductions in non-fatal myocardial infarction, recurrent angina, and unplanned cardiac rehospitalization. Multivariate Cox regression identified early evolocumab as an independent protective factor against 3-month MACE (HR = 0.42, 95% CI: 0.25–0.71, P = 0.001). No significant between-group difference in adverse events was observed (5.43% vs. 4.26%, P = 0.715). Conclusion Early evolocumab add-on therapy to high-intensity statin achieves potent lipid-lowering and anti-inflammatory effects, improves 3-month clinical outcomes, and has an acceptable safety profile in non-revascularized CHIP-NSTEACS patients. This strategy represents a promising optimized pharmacotherapy for this ultra-high-risk population. Limitations Single-center retrospective design and short follow-up period limit generalizability.
No takes yet. Share an insight, caveat, or question.
Liu et al. (2026) conducted a cohort in Complex high-risk indicated non-revascularized non-ST-elevation acute coronary syndrome (CHIP-NSTEACS) (n=186). Early evolocumab add-on therapy vs. High-intensity statin monotherapy was evaluated on 3-month major adverse cardiovascular events (MACE) (HR 0.42, 95% CI 0.25-0.71, p=0.001). Early evolocumab combined with a high-intensity statin significantly reduced 3-month major adverse cardiovascular events by 58% (HR 0.42) compared to statin monotherapy in non-revascularized CHIP-NSTEACS patients.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: